Shanghai Junshi Biosciences (HKG:1877, SHA:688180) obtained approval from Australia's Therapeutic Goods Administration (TGA) to market the drug toripalimab, according to a Hong Kong Stock Exchange disclosure on Jan. 17.

The TGA approved the new chemical entity application for toripalimab in combination with cisplatin and gemcitabine as a treatment for adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma or NPC.

Toripalimab was also approved as a single agent to treat adults with unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy, the filing said.

The pharmaceutical company's Shanghai shares rose more than 1% and Hong Kong shares climbed less than 2% in recent trade.